diff options
| author | mac <ra@afu.re> | 2025-11-25 09:00:59 -0500 |
|---|---|---|
| committer | mac <ra@afu.re> | 2025-11-25 09:00:59 -0500 |
| commit | 45272999c6c4bcfcc08aeaf03908e36be5db7570 (patch) | |
| tree | bf7d879eec9c714994277a39dc938e0db2340aa8 /Finance/Tickers | |
| parent | 5abe0f18274b0ea87c0413f1e04fc3721b8cd25d (diff) | |
Auto from mac asahi - Tue 25 Nov 2025 09:00:59 AM EST
Diffstat (limited to 'Finance/Tickers')
| -rw-r--r-- | Finance/Tickers/CRMD.md | 23 | ||||
| -rw-r--r-- | Finance/Tickers/index.md | 2 |
2 files changed, 25 insertions, 0 deletions
diff --git a/Finance/Tickers/CRMD.md b/Finance/Tickers/CRMD.md new file mode 100644 index 0000000..139b726 --- /dev/null +++ b/Finance/Tickers/CRMD.md @@ -0,0 +1,23 @@ +# CorMedix inc. - NASDAQ:CRMD + +Story parrallel to suganmadex introduction + +Taurolock & Taurolidine + +Solving CRBST (catherer blood stream infection) + +CRMD instead of using Citrate develloped their own solution. +Pairing Taurolidine with heparin making DefenCath +DefenCath FDA approved in Nov 2023 +Target: Hospitals & dyalisis clinics + +Total Market potential more or less ~170,000 patient +now around ~3000 patient +already signed contracts for 70% TAM (?) + +looking at end 2027$ + +~250$ per vial +CRBST cost around 63,000$ per case, nothing compared to 250$ + +NTAP end Nov 2026 diff --git a/Finance/Tickers/index.md b/Finance/Tickers/index.md index e1419a2..6d63531 100644 --- a/Finance/Tickers/index.md +++ b/Finance/Tickers/index.md @@ -26,6 +26,8 @@ [[CRDO]] +[[CRMD]] + [[CSV]] [[CSX]] |